Extension to TerugBetaalRegeling Acecort®
Recently also Acecort® 2 and 3 mg tablets have been registered. The health insurer will not reimburse the cost in full. The producer of this medicine…
There are no tracking cookies being placed via this website. The Company also does not process any personal data from your visit to this website. Therefore, you will not find either a cookie notice…
General information
The pharmacist has dispensed Cholestagel® 625mg to the patient. The health insurer will not reimburse the cost of this prescription in full. The producer of this…
Termination TerugBetaalRegeling Tecfidera®
As of December 1, 2021, a Personal Contribution for Tecfidera is no longer required. Health insurers will once again fully reimburse the medicine. The…
Termination TerugBetaalRegeling Fragmin®2500
From January 1st 2022 onwards, the reimbursement scheme for FRAGMIN (dalteparine)2500 INJVLST 12.500IE/ML WWSP 0,2ML will be terminated. The…
Reimbursement Scheme Forxiga® (dapagliflozin) 10 mg for patients with diabetes partially stopped
From September 1st 2021 onwards, Forxiga® (dapagliflozin) 10 mg for the treatment of adults with type…
Reimbursement Scheme Forxiga® (dapagliflozine) 10 mg - Chronic Kidney Disease
The health insurer does not yet fully reimburse Forxiga® (dapagliflozine) 10 mg for the treatment of chronic kidney…
Termination TerugBetaalRegeling Forxiga® - Hartfalen
From July 1st 2021 onwards, Forxiga® (dapagliflozine) 10 mg for the treatment of heart failure with reduced ejection fraction (HFrEF) is fully…
Amendment to TerugBetaalRegeling Lokelma®
TBR Nederland hereby informs you that it will make a change to a repayment scheme starting from now. This concerns the medicine Lokelma® 5g and 10g.
The…
